References
- Patruno C, Fabbrocini G, Napolitano M. Clinical phenotypes of atopic dermatitis of the adult. Ital J Dermatol Venerol. 2021;156(6):721–722. doi: 10.23736/S2784-8671.20.06532-3
- Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78–88. doi: 10.18176/jiaci.0138
- Napolitano M, Megna M, Patruno C, et al. Adult atopic dermatitis: a review. G ital Dermatol Venereol Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia. 2016;151(4):403–411.
- Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729–747. doi: 10.1111/jdv.13599
- David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21–37.
- Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi: 10.3390/ijms22084130
- Mandlik DS, Mandlik SK. Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. Immunopharmacol Immunotoxicol. 2021;43(2):105–125. doi: 10.1080/08923973.2021.1889583
- Napolitano M, Marasca C, Fabbrocini G, et al. Adult atopic dermatitis: new and emerging therapies. Expert Rev Clin Pharmacol. 2018;11(9):867–878. doi: 10.1080/17512433.2018.1507734
- Furue M. Regulation of filaggrin, Loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci. 2020;21(15):5382. doi: 10.3390/ijms21155382
- Kim BE, Leung DY, Boguniewicz M, et al. Loricrin and involucrin expression is downregulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332–337. doi: 10.1016/j.clim.2007.11.006
- Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic Dermatits filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150–155. doi: 10.1016/j.jaci.2007.04.031
- Napolitano M, Fabbrocini G, Martora F, et al. Role of aryl hydrocarbon receptor activation in inflammatory chronic skin diseases. Cells. 2021;10(12):3559. doi: 10.3390/cells10123559
- Napolitano M, Fabbrocini G, Potestio L, et al. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis. Dermatol Ther. 2022;35(8):e15588. doi: 10.1111/dth.15588
- Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J DermatolTreat. 2022 Nov;33(7):3028–3033. doi: 10.1080/09546634.2022.2102121
- Napolitano M, Nocerino M, Picone V, et al. Dupilumab for the treatment of atopic dermatitis in transplant patients: two case reports and literature review. Dermatol Ther. 2022;35(4):e15324. doi: 10.1111/dth.15324
- Liu F-T, Goodarzi H, Chen H-Y. IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol. 2011;41(3):298–310. doi: 10.1007/s12016-011-8252-4
- Sullivan M, Silverberg NB. Current and emerging concepts in atopic dermatitis pathogenesis. Clin Dermatol. 2017 Jul;35(4):349–353. doi: 10.1016/j.clindermatol.2017.03.006
- Otsuka A, Nomura T, Rerknimitr P, et al. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunol Rev. 2017;278(1):246–262. doi: 10.1111/imr.12545
- Vollenweider S, Saurat JH, Rocken M, et al. Evidence suggesting involvement of interleukin-4 (IL-4) production in spontaneous in vitro IgE synthesis in patients with atopic dermatitis. J Allergy Clin Immunol. 1991 Jun;87(6):1088–1095. doi: 10.1016/0091-6749(91)92154-S
- Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003 Apr;111(4):677–690. quiz 691. doi: 10.1067/mai.2003.1333
- Fish SC, Donaldson DD, Goldman SJ, et al. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol. 2005 Jun 15;174(12):7716–7724. doi: 10.4049/jimmunol.174.12.7716
- Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J Mol Biol. 2013;425(8):1330–1339. doi: 10.1016/j.jmb.2013.01.024
- Eli Lilly and Company. Lebrikizumab dosed every four weeks maintained durable skin clearance in Lilly’s phase 3 monotherapy atopic dermatitis trials. Indianapolis, Indiana, USA: Eli Lilly and company. Sep 8, 2022.
- Silverberg JI, Guttman-Yassky E, Thaçi D, et al. ADvocate1 and ADvocate2 investigators. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023 Mar 23;388(12):1080–1091. doi: 10.1056/NEJMoa2206714
- Study to assess the safety and efficacy of lebrikizumab (LY3650150) in adolescent participants with moderate-to-severe atopic dermatitis (ADore). [cited 2023 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT04250350?term=NCT04250350&draw=2&rank=1.
- Study do assess long-term safety and efficacy study of lebrikizumab in participants with moderate-to-severe atopic dermatitis. [cited 2023 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT04392154?term=NCT04392154&draw=2&rank=1.
- A study of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis Previously treated with Dupilumab. [cited 2023 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT05369403?term=NCT05369403&draw=2&rank=1.
- A study of lebrikizumab to assess the safety and efficacy of adult and adolescent participants with moderate-to-severe atopic dermatitis and skin of color. [cited 2023 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT05372419?term=NCT05372419&draw=2&rank=1.
- A study of lebrikizumab (LY3650150) in participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis. [cited 2023 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT05559359?term=NCT05559359&draw=2&rank=1.
- Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9(4):271–285. doi: 10.1038/nri2526
- Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134. Annu Rev Immunol. 2010;28:57–78. doi: 10.1146/annurev-immunol-030409-101243
- Webb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and auto- immunity: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(3):312–332. doi: 10.1007/s12016-015-8498-3
- Lé AM, Torres T. OX40-OX40L inhibition for the treatment of atopic dermatitis-focus on rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753. doi: 10.3390/pharmaceutics14122753
- Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(2):482–493. doi: 10.1016/j.jaci.2018.11.053
- Study to assess the safety and efficacy of GBR830 compared to placebo, in adults with moderate-to-severe atopic dermatitis. [cited 2023 Apr 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02683928?term=NCT02683928&cond=Atopic+Dermatitis&draw=2&rank=1.
- A phase 2b study to evaluate the efficacy and safety of ISB 830 in adults with moderate to severe atopic dermatitis. [cited 2023 Apr 10]. Available form https://clinicaltrials.gov/ct2/show/NCT03568162?term=NCT03568162&cond=Atopic+Dermatitis&draw=2&rank=1.
- Saghari M, Gal P, Gilbert S, et al. OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005. Clin Pharmacol Ther. 2022;111(5):1121–1132. doi: 10.1002/cpt.2539
- Weidinger S, Bieber T, Reich MJ, et al. Treatment with amlitelimab–A novel non-depleting, non-cytotoxic antiOx40ligand monoclonal antibody–reduces IL-22 serum levels in aphase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2023;189(5):531–539. doi: 10.1093/bjd/ljad240
- Study testing response effect of KY1005 against moderate-to-severe atopic dermatitis, the STREAM-AD study (STREAM-AD). [cited 2023 Apr 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT05131477?term=NCT05131477&cond=Atopic+Dermatitis&draw=2&rank=1.
- Long-term safety and efficacy evaluation of Amlitelimab in adult participants with moderate to severe atopic dermatitis. [cited 2023 Apr 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT05492578?term=NCT05492578&cond=Atopic+Dermatitis&draw=2&rank=1.
- Lé AM, Torres T. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab.Pharmaceutics. 2022;14(12):2753. [cited 2022 Dec 8]. Available from: doi: 10.3390/pharmaceutics14122753.
- Elsner JS, Carlsson M, Stougaard JK, et al. The OX40 Axis is associated with both systemic and local involvement in atopic dermatitis. Acta Derm Venereol. 2020;100(6):adv00099. doi: 10.2340/00015555-3452
- Wang YH, Liu YJ. OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J Clin Invest. 2007;117(12):3655–3657. doi: 10.1172/JCI34182
- Guttman-Yassky E, Simpson EL, Reich K, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023 Jan 21;401(10372):204–214. doi: 10.1016/S0140-6736(22)02037-2
- A study assessing rocatinlimab (AMG 451) monotherapy in moderate-to-severe atopic dermatitis (ROCKET-Horizon). [cited 2023 Apr 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT05651711?term=NCT05651711&draw=2&rank=1.
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE). [cited 2023 Apr 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT05398445?term=NCT05398445&draw=2&rank=1.
- A study assessing rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitors in adult participants with moderate-to-severe atopic dermatitis (ROCKET-SHUTTLE). [ cited 2023 Apr 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT05724199?term=NCT05724199&draw=2&rank=1.
- A study to assess the safety, tolerability, and efficacy of rocatinlimab in adolescent participants with moderate-to-severe atopic dermatitis (ROCKET-Orbit). [cited 2023 Apr 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT05633355?term=NCT05633355&draw=2&rank=1.
- Alves-Filho JC, Sônego F, Souto FO, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med. 2010;16(6):708–712. doi: 10.1038/nm.2156
- A study to assess the efficacy, safety, and pharmacokinetic profile of Etokimab (ANB020) in adult participants with moderate-to-severe atopic dermatitis (ATLAS). [ cited 2023 Apr 11]. Available from: https://clinicaltrials.gov/study/NCT03533751?cond=Atopic%20Dermatitis&term=NCT03533751&rank=1&tab=results.
- Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673–680. doi: 10.1038/ni805
- Zhu Z, Oh MH, Yu J, et al. The role of TSLP in IL-13-induced atopic march. Sci Rep. 2011;1(1):23. doi: 10.1038/srep00023
- Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4):1013–1021. doi: 10.1016/j.jaad.2018.11.059
- A dose ranging placebo-controlled double-blind study to evaluate the safety and efficacy of tezepelumab in atopic dermatitis. [cited 2023 Apr 11]. Available from https://clinicaltrials.gov/ct2/show/NCT03809663?term=NCT03809663&cond=Atopic+Dermatitis&draw=2&rank=1.
- Boutet M-A, Nerviani A, Pitzalis CI-3. IL-37, and IL-38 cytokines in skin and joint inflammation: a comprehensive review of their therapeutic potential. Int J Mol Sci. 2019;20(6):1257. doi: 10.3390/ijms20061257
- Hernandez-Santana YE, Giannoudaki E, Leon G, et al. Current perspectives on the interleukin-1 family as targets for inflammatory disease. Eur J Immunol. 2019;49(9):1306–1320. doi: 10.1002/eji.201848056
- Iznardo H, Puig L. 1IL-1 family cytokines in inflammatory dermatoses: pathogenetic role and potential therapeutic implications. Int J Mol Sci. 2022;23(16):9479. doi: 10.3390/ijms23169479
- Boraschi D, Italiani P, Weil S, et al. The family of the interleukin-1 receptors. Immunol Rev. 2018;281(1):197–232. doi: 10.1111/imr.12606
- Iznardo H, Puig L. IL-1 family cytokines in inflammatory dermatoses: pathogenetic role and potential therapeutic implications.Int J Mol Sci. 2022;23(16):9479. [Published 2022 Aug 22] doi: 10.3390/ijms23169479.
- Cavalli G, Colafrancesco S, Emmi G, et al. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20(3):102763. doi: 10.1016/j.autrev.2021.102763
- A study of bermekimab (JNJ-77474462) in the treatment of participants with moderate to severe atopic dermatitis (GENESIS). [cited 2023 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04791319?term=NCT04791319&cond=Atopic+Dermatitis&draw=2&rank=1.
- Patruno C, Fabbrocini G, De Lucia M, et al. Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib. Dermatol Ther. 2022;35(11):e15788. doi: 10.1111/dth.15788